Information deficits in the summary of product characteristics preclude an optimal management of drug interactions: a comparison with evidence from the literature

ObjectiveTo compare comprehensiveness and accuracy of drug interaction information in the German summary of product characteristics (SPC) with current evidence from the literature and to evaluate the SPC’s usefulness with respect to management of drug interactions.MethodsInformation on clinically relevant drug interactions was compared between the SPC and three standard information sources on drug interactions (DRUGDEX, Hansten/Horn’s Drug Interactions Analysis and Management, Stockley’s Drug Interactions) according to five consecutive criteria (inclusion, appropriateness of class labelling, effect description, management recommendation, explicit dose adjustment). Using medication data of an outpatient population (n=4,949), we determined what percentage of insufficiently characterized combinations indeed occurred in outpatients treated with combination drug therapy.ResultsOnly for 33% (192/579) of the evaluated combinations did SPCs provide drug interaction information equivalent to the evidence from the published literature. Of the clinically relevant drug interactions, 16% were completely missing and 51% were insufficiently characterized compared with standard sources. Explicit management recommendations were either missing or differed from standard sources in 18% of the evaluated pairs of compounds. Of these missing or insufficiently characterized combinations, 12% (47/387) were indeed prescribed to outpatients. Those drug combinations for which the interaction potential was not mentioned in the SPC were received by 0.6% (32/4,949) of patients, and 4% (192/4,949) of patients received combinations that had insufficiently characterized drug interactions.ConclusionsIf physicians only rely on SPC information for drug interactions, adverse events due to lacking management recommendations may occur. To meet the SPCs claim of being the basis of information for health professionals on how to use medicinal products safely and effectively, information on drug interactions should be thoroughly up-dated and expanded.

[1]  W. Haefeli,et al.  Dose individualisation in patients with renal insufficiency: does drug labelling support optimal management? , 2004, European Journal of Clinical Pharmacology.

[2]  Drug labeling should be kept current , 2003, Clinical pharmacology and therapeutics.

[3]  F. Haaijer-Ruskamp,et al.  The development of polypharmacy. A longitudinal study. , 2000, Family practice.

[4]  T. Walley,et al.  Influences on GPs' decision to prescribe new drugs-the importance of who says what. , 2003, Family practice.

[5]  Aileen B. Sedman,et al.  A longitudinal study , 1987 .

[6]  I. Anderson,et al.  Incorrect overdose management advice in the Physicians' Desk Reference. , 1997, Annals of emergency medicine.

[7]  Jenny Field,et al.  General practitioners' perceptions of the route to evidence based medicine: a questionnaire survey , 1998, BMJ.

[8]  J K Aronson Drug interactions-information, education, and the British National Formulary. , 2004, British journal of clinical pharmacology.

[9]  M. Bonati,et al.  Prescribing information in 26 countries: a comparative study , 2003, European Journal of Clinical Pharmacology.

[10]  R. Kapp Stockley’s Drug Interactions, 6th Edition , 2004 .

[11]  Jennifer C. Lin,et al.  The Effect of Converting from Pravastatin to Simvastatin on the Pharmacodynamics of Warfarin , 1999, Journal of clinical pharmacology.

[12]  J. Hallas,et al.  Polypharmacy and the risk of drug-drug interactions among Danish elderly. A prescription database study. , 1998, Danish medical bulletin.

[13]  H. Brenner,et al.  Drug interactions in primary care: Impact of a new algorithm on risk determination , 2004, Clinical pharmacology and therapeutics.

[14]  H. Pan Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase , 2005, European Journal of Clinical Pharmacology.

[15]  J S Cohen,et al.  Dose discrepancies between the Physicians' Desk Reference and the medical literature, and their possible role in the high incidence of dose-related adverse drug events. , 2001, Archives of internal medicine.

[16]  W. Haefeli,et al.  Requirements for a successful implementation of drug interaction information systems in general practice: results of a questionnaire survey in Germany , 2004, European Journal of Clinical Pharmacology.

[17]  Raymond L. Woosley,et al.  Assessment and reporting of clinical pharmacology information in drug labeling , 2000, Clinical pharmacology and therapeutics.